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Abstract
The pulmonary complications of sickle cell disease (SCD) have a high morbidity and
mortality. Fatal pulmonary complications occur in 20% of adults;  those with sickle
chronic  lung  disease  (SCLD)  and  pulmonary  hypertension  have  a  significantly
increased  mortality.  Treatment  of  SCLD is  only  supportive.  Recurrent  acute  chest
syndrome (ACS) episodes are the major risk factor for SCLD, and ACS is the leading
cause of death. Adults with SCD tend to have restrictive lung function abnormalities,
whereas,  in  children,  obstructive  abnormalities  are  more  frequent.  Lung  function
abnormalities are common even in young children and may reflect their chronic anaemia
and increased pulmonary capillary blood volume, which increases airway obstruction
and  may  be  responsible  for  their  increased  wheezing.  Whether  more  aggressive
treatment of anaemia would improve lung function and long-term outcomes merits
testing. Children with SCD experience a decline in lung function, which is most rapid
in  younger  children  in  whom  ACS  episodes  are  most  common  highlighting  the
importance of identifying effective strategies to prevent and optimally treat ACS.
Keywords: Sickle cell disease, Acute chest syndrome, Obstructive lung function ab-
normalities, Restrictive lung function abnormalities
1. Introduction
The pulmonary complications of sickle cell disease (SCD) have a high morbidity and mortality
with fatal pulmonary complications occurring in 20% of adults. Despite significant improve-
ments in life expectancy in individuals with SCD, the median age of death for women is 48
years and for men 42 years. Young adults can develop sickle chronic lung disease (SCLD),
which consists of restrictive lung disease, abnormal diffusing capacity and hypoxaemia. Those
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with SCLD and pulmonary hypertension have a significantly increased mortality. Treatment
of SCLD is only supportive. Recurrent acute chest syndrome (ACS) episodes are the major risk
factor for SCLD and ACS is the leading cause of death. Prevention and optimum management
of ACS episodes then should reduce SCLD occurrence. ACS episodes occur most frequently
in young children with SCD and lung function abnormalities are common in childhood. In
this  chapter,  the  aetiology,  pathogenesis  and  management  of  acute  chest  syndrome  are
discussed.  The presentation of  SCLD is  briefly summarised as this  occurs in adults,  but
included here as it is an important adverse outcome of ACS episodes. Pulmonary hypertension
is discussed elsewhere (see Chapter x), but the impact on those with lung function abnormal-
ities is emphasised in this chapter. Lung function abnormalities in children associated with
SCD are described as the factors influencing the deterioration in lung function suffered by
children with SCD. Recommendations are made with regard to routine respiratory monitor-
ing.
2. Acute chest syndrome (ACS)
2.1. Presentation
The overall incidence of ACS as indicated by the Cooperative Study of Sickle Cell Disease
(CSSCD) is 10.5 per 100 patient years [1]. ACS episodes occur more commonly in children than
adults. Fifty percent of SCD children will have an ACS episode prior to the age of 10 years and
the highest incidence of ACS occurs in children aged between 2 and 4 years of age [2]. ACS
episodes are characterised by fever, chest pain and respiratory symptoms and essential to
making the diagnosis with a new pulmonary infiltrate on chest radiograph. Fever and cough
are more common in young children who, compared to adults, are more likely to have isolated
upper lobe disease. Adults tend to suffer chest pain, haemoptysis and shortness of breath; their
middle and lower lobes are more frequently affected than the upper lobes. Severe respiratory
failure, necessitating mechanical ventilation, occurs in approximately 10–15% of affected
patients. Recurrence is common, occurring in 80% of those who have had a prior episode.
Follow-up of 293 patients aged between 3 and 20 years for 21 months demonstrated that a
history of acute pulmonary events and younger age were independently associated with
developing a new ACS episode [3]. In children less than 4 years of age who had had an ACS
episode, one study demonstrated that the majority were hospitalised for ACS or severe pain
within 1 year, emphasising the need for an effective therapeutic intervention in that high risk
group [4].
2.2. Risk factors
The incidence of ACS varies according to the haemoglobin genotype being commonest in
those with HbSS and much less common in those with HbSC [2]. In a retrospective review,
ACS episodes also appeared less severe in children with HbSC compared to those with
HbSS as indicated by a significantly shorter hospital stay [5]. The sickle cell mutation has
arisen on at least five separate occasions, on four occasions in Africa and one occasion in
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Saudi Arabia or India [2]. The prevalence and recurrence of ACS episodes in Saudi Arabia
are relatively low as compared to patients in Africa; this may be due to the interaction be-
tween SCD and the ‘Asian’ haplotype [6], which is known to be associated with a higher
fetal haemoglobin (HbF) level. ACS hospitalisation has been shown to be associated with a
single nucleotide polymorphism (SNP)-defined beta globin cluster [7]. The risk for ACS is
increased by certain endothelin NO synthase gene polymorphisms [8]. A heme oxygenase-1
gene promoter was associated with a reduced incidence of ACS hospitalisation [9]. A gene-
centric association study found an association between ACS and rs6141803, the SNP located
8.2 kb upstream of COMMD7, a gene highly expressed in the lung that interacts with nucle-
ar factor-kB signalling [10].
High haemoglobin levels predispose to vascular obstruction and increase the risk of compli-
cations, such as ACS. High HbF levels inhibit the polymerisation of HbS and hence the higher
the HbF level the lower the occurrence of ACS episodes [2]. Leucocytes release free radicals,
elastase, pro-inflammatory mediators and cytokines, hence the occurrence of ACS episodes
are directly proportional to the steady-state white blood cell count [11].
In approximately 10% of patients, an ACS is precipitated by a pulmonary fat embolism;
affected patients tend to be older, have a lower mean oxygen saturation at presentation and
have a more severe clinical course. Typically, the pulmonary signs and symptoms are preceded
by bone pain. Affected individuals may have systemic signs of a fat embolism, including
changes in their mental state, thrombocytopaenia and petechiae. Infarction of the bone marrow
may result in fat embolisation. This can activate pulmonary secretory phospholipase A2
liberating free fatty acids. Arachidonic acid causes vasoconstriction and oleic acid upregulation
of the vascular cell adhesion molecule (VCAM-1). Splinting resulting from bony thorax
infarction leads to hypoventilation and atelectasis with accompanying hypoxia and hence
sickling. The hypoventilation can be compounded by suppression of respiration by opoid
administration. Infection causes approximately 30% of ACS episodes. The seasonal variation
in ACS episodes in young children likely reflects the increase in viral infections in young
children during the winter months. Children presenting with fever have an increased risk of
developing an ACS episode if they have had a previous ACS episode, upper respiratory tract
infection symptoms, non-compliance to penicillin, an absolute neutrophil count greater than
9 × 10(9)/l and haemoglobin less than 8.6 g/dl [12]. In a multicentre study, 27 different pathogens
were identified, but Chlamyidia pneumoniae was the most frequent pathogen, followed by
Mycoplasma pneumoniae and respiratory syncytial virus. Parvovirus B10 has been associated
with marrow necrosis and a particularly severe form of ACS.
In the Cooperative Study for Sickle Cell Disease before 6 months of age in which patients were
followed beyond 5 years of age, a clinical diagnosis of asthma was made in 17% of the cohort.
Asthma was associated with more frequent ACS episodes [13]. In a retrospective review of
inpatient episodes for ACS, a previous history of asthma or wheezing was more common in
children with HbSC than in those with HBSS causing the authors to speculate that asthma and
wheezing may be more significant risk factors for ACS episodes [5].
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2.3. Risk factors for recurrent ACS episodes
In a cohort of 159 children followed from birth to a median of 14.7 years, an ACS episode prior
to 4 years, female gender, wheezing with shortness of breath and two or more positive skin
prick tests were associated with future ACS episodes, but airway obstruction and a broncho-
dilator response were not [14]. Asthma has been reported to be a risk factor for recurrent ACS
episodes in SCD children in Jamaica [15].
2.4. Pathogenesis
The levels of inflammatory cytokines are increased in ACS. Nitric oxide (NO) levels, however,
are reduced; this is due to a number of reasons. ‘Free’ haemoglobin in the plasma scavenges
NO. Hypoxia reduces NO production by inhibition of NO synthase and activated macrophages
and leuocytes release free radical species that inactivate NO. Adhesion is increased when there
are low NO levels as NO inhibits the upregulation of VCAM-1. NO also inhibits endothelin-1
production. In addition, there is a lack of inhibition of platelet activation and further poten-
tiation of microvascular occlusion and the release of vasoconstrictor metabolites such as
thromboxane A2. Sickle red blood cells, due to the greater auto-oxidation of HbS compared to
HbA, produce greater levels of oxygen-related radicals including superoxide, hydrogen
peroxide and peroxynitrite. There are also lower levels of antioxidant enzyme systems, e.g.
superoxide dismutase, catalyse and glutathione peroxidate. The sickle cells occlude vessels
causing vascular injury, especially to organs with sluggish circulation such as atelectatic areas
of the lung. Neutrophils are more adherent to endothelin cells in SCD patients and this has
been associated with ACS episodes.
2.5. Management
Broad spectrum antibiotics should be given, including macrolides or quinolones to treat
atypical organisms. The choice of antibiotics should be guided by the patient’s clinical
condition and the ‘local’ pathogens. Oxygen therapy should be used to treat any hypoxaemia.
There may, however, be a poor correlation of pulse oximetry readings with arterial oxygen
tensions (see below) and hence blood gas analysis should be undertaken if there is suspicion
of hypoxia. Indications for escalation of respiratory support, which is most likely in those with
extensive, pulmonary involvement, are increasing hypoxia and dyspnoea and the pH follow-
ing below 7.35. In such patients, non-invasive ventilation has been demonstrated to improve
oxygenation and reduce heart rate [16], but may be poorly tolerated. Patients should be
carefully rehydrated as SCD patients are susceptible to fluid overload; hydration should be
limited to 1.5 times the maintenance fluid volume to avoid further impairment of lung function
by aggravating vascular leak in the lungs. In ACS patients with hypoxia, simple or exchange
transfusion can rapidly increase oxygenation [17]. An alveolar-arterial oxygen gradient >30
mmHg has been associated with a worse severity score and higher need for transfusion [17].
To improve the oxygen-carrying capacity of the blood and reduce the proportion of sickle
haemoglobin a transfusion is given. In those patients with a relatively high haematocrit an
exchange transfusion is administered, as a simple transfusion under such circumstances would
increase the viscosity of the blood. Non-randomised trials have not shown any benefit of
Sickle Cell Disease - Pain and Common Chronic Complications114
exchange transfusion over simple transfusion [18, 19]; nevertheless in more severe cases
requiring mechanical ventilation, particularly if a simple transfusion has not improved the
patient, exchange transfusion is recommended [2]. Indications to proceed to an exchange
transfusion include increasing hypoxia, increasing respiratory rate, reducing platelet count
and multilobar disease. The aim being to keep the haemoglobin level at 10–11 g/dl. Analgesia
should be given to control pain, but the amount limited to avoid respiratory depression. Patient
controlled analgesia devices may reduce the risk of narcotic-induced hypoventilation [20].
Intercostal nerve block with a long acting local anaesthetic can alleviate chest wall pain and
has the advantage of reducing the amount of systemic analgesia needed to control pain [2].
Inhaled NO (20–80 ppm) in patients with ACS and pulmonary hypertension has been reported
to result in rapid and significant pulmonary vasodilation and improvement in oxygenation
[21, 22]. Inhaled NO increases the oxygen affinity of HbS. A large prospective randomised trial,
however, failed to show any significant differences in the time to resolution of crisis, length of
hospitalisation, pain scores, cumulative opioid usage and rate of ACS between the nitric oxide
and the placebo groups [23]. Approximately 25% of patients wheeze during an ACS episode
and may benefit from bronchodilator administration [18], but the effect of bronchodilators on
long-term outcome has not been investigated in randomised controlled trials. In a small
Randomised controlled trial, dexamethasone administered to children with mild to moder-
ately severe ACS was associated with a 40% reduction in the length of hospitalisation, a shorter
duration of supplementary oxygen requirement and less need for analgesia [24]. Such
outcomes are biologically plausible, as corticosteroids modulate endothelin cell adhesion
molecule expression including VCAM-1 and have an inhibitory effect on phospholipase A2.
Readmission after an ACS episode, however, has been demonstrated to be more common in
those who reported use of an inhaler or a nebuliser at home or had received corticosteroids
for the ACS episode [25].
2.6. Prevention
Fetal haemoglobin (HbF) inhibits polymerisation of deoxyhaemoglobin S and the level of HbF
predicts the severity of the condition being inversely related to the mortality. There are a
number of agents that raise HbF levels. One such is hydroxyurea that is a ribonuclease
reductase inhibitor blocking DNA synthesis. The HbF level is raised due to the resultant bone
marrow suppression. Additionally, hydroxyurea as an NO donor reduces VCAM-1 production
and hence decreases sickle cell adhesion to the vascular endothelin. In an RCT involving adults,
hydroxyurea reduced the incidence of ACS [26]. The systematic review of studies to date
concluded that hydroxyurea is effective and safe in adults severely affected by sickle cell
anaemia. The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was an RCT of daily
oral hydroxurea in children with sickle cell anaemia aged 9–18 months. The trial failed to
achieve its primary aim which was to determine whether daily hydroyurea would reduce
spleen and renal damage by at least 50%. There were, however, significantly fewer sickle cell
disease related events in the hydroxurea group, including ACS episodes [27]. Hydoxyurea,
however, may cause cytopaenias and patients must be carefully monitored, especially early in
the administration of therapy, which may explain why some physicians are reluctant to
prescribe it [28]. The summary of the 2014 evidence-based report by expert panel members
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gave a recommendation of moderate strength regarding offering treatment with hydroxyurea
without regard to the presence of symptoms for infants, children and adolescents [29]. Chronic
transfusion in patients with a history of recurrent or severe episodes has been demonstrated
by both retrospective review [30] and randomised trial [31] to reduce the frequency of ACS
episodes. Routine use of incentive spirometry is recommended in SCD patients admitted to
hospital with chest or bone pain. Such management in a randomised trial was associated with
a lower rate of pulmonary complications (atelectasis or infiltrates) as seen on a subsequent
chest radiograph [32]. A retrospective review demonstrated that introduction of an evidence-
based guideline initiating mandatory incentive spirometry in children with SCD admitted for
non-respiratory complaints resulted in a reduced number of transfusions and ACS episodes
[33]. Stem cell transplantation in adults and children has been associated with no recurrence
of painful crisis in those with stable engraftment [34]. The best results were obtained in young
children who have HLA-identical sibling donors and transplanted early in the course of their
disease [35]. In certain paediatric populations the success rate is 85–90% [36].
2.7. Outcome
The overall mortality for ACS is 3%, but 9% in adults [18]. The primary cause of death is
respiratory failure from pulmonary emboli and bronchopneumonia. In one study [37], 60% of
severe ACS episodes were associated with pulmonary hypertension which is associated with
a higher risk of death. The incidence of acute kidney injury is higher in patients with ACS and
pulmonary hypertension and correlates with the severity of the ACS [38]. Young children with
a greater number of ACS episodes have a greater decline in lung function (see below) [39]. In
young adults, the greater the number of ACS episodes the greater the reduction in lung
function [40].
3. Pulmonary hypertension
In a screening study, 32% of patients had a tricuspid regurgitant jet velocity (TRV) by Doppler
echocardiography of greater or equal to 2.5 m/s which corresponds to a Pulmonary artery
systolic pressure of 25–35 mmHg (approximately two standard deviations above the mean).
Despite mildly elevated TRV values, the prospective mortality was high with a tenfold increase
in the odds ratio for death [41]. Echocardiography, however, may overestimate the prevalence
of pulmonary hypertension [42]. Pulmonary hypertension in SCD is characterised by progres-
sive obliteration of the pulmonary vasculature. Possible causes include chronic hypoxic stress
causing irreversible remodelling of the pulmonary vasculature, recurrent pulmonary throm-
boembolism, sickle cell related vasculopathy and pulmonary scarring from recurrent ACS
episodes. An elevated TRV has been reported in 11–31% of children and adolescents with SCD
[43, 44]. The clinical significance is not known although an elevated TRV in children has been
associated with a decline in exercise capacity [45].
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4. Sickle chronic lung disease (SCLD)
SCLD is a progressive disease with an insidious onset progressing to end-stage respiratory
failure, characterised by hypoxemia, restrictive lung disease, cor pulmonale and chest
radiograph evidence of diffuse interstitial fibrosis. Recurrent ACS episodes result in damage
to the lung parenchyma resulting in restrictive lung disease. In a study of 319 adults with SCD,
74% had restrictive lung function abnormalities [46]. The mean survival of SCD patients with
chronic lung disease and elevated pulmonary artery pressures can be as short as 2 years.
Sudden death in SCLD patients with pulmonary hypertension is common due to pulmonary
thromboembolism, systemic hypotension and cardiac arrhythmia. Adult SCD patients,
therefore, should be screened for pulmonary hypertension with echocardiography as,
although initially the patients may be asymptomatic, their condition progresses and they suffer
worsening hypoxia and chest pain with impaired exercise tolerance.
5. Asthma and outcomes of SCD
Asthma has been associated with adverse outcomes in SCD patients. Asthma has been reported
to be more common in those with ACS [13] and in particular with recurrent ACS episodes [15].
In one series, after controlling for established risk factors, individuals with sickle cell anaemia
and asthma had more than a two fold increased risk of mortality [47]. In another series [48],
after adjusting for baseline lung function, current asthma and smoking were significantly
associated with mortality during a 10-year period in young adults [48]. Patients with SCD
frequently wheeze and asthma may have been over diagnosed in previous studies that used
a physician’s diagnosis of asthma rather than more objective tests such as determination of
bronchial responsiveness. In a retrospective study, asthma and wheezing were independent
risk factors for increased painful episodes and only wheezing was associated with more ACS
episodes [49]. In an observational study in SCD adults, the ACS rate, lung function or risk of
death was not significantly related to a diagnosis of asthma. Whereas those who had recurrent
severe episodes of wheezing compared to those without wheeze had twice the number of ACS
episodes, poorer lung function and an increased risk of death [50].
6. Lung function abnormalities
Obstructive lung abnormalities are reported in young children [51, 52] with restrictive
abnormalities becoming more prominent with advancing age [53]. Airway hyper-responsive-
ness (AHR) to methacholine has been reported to be more common in SCD children, but not
related to signs or symptoms of allergy [54]. There is great variation reported in the response
to bronchial challenges from 0% in one study [55] to 78% [56] in another. Similarly, the response
to bronchodilator varies from no difference compared to controls [53], but others [15, 57]
reporting a much higher response. Nocturnal desaturation episodes, possibly due to obstruc-
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tive sleep apnoea, may occur in up to 40% of children and adolescents. Oxygen saturation
monitoring, however, may be inaccurate as oximeters do not differentiate between oxyHb and
carboxyhaemoglobin which is raised in some patients.
6.1. Exercise capacity
There have been few studies investigating the cardio-respiratory responses of patients with
sickle cell anaemia to exercise. Children with SCD have been reported to have more adipose
tissue with reduced fitness and exercise performance [58]. Exercise capacity has been reported
to be related to the baseline degree of anaemia and be significantly lower in subjects with a
history of recurrent ACS [59]. The metabolic changes imposed by exercise may initiate sickling
and vaso-occlusive episodes. Patients, therefore, are advised to start exercise slowly and
progressively, to maintain hydration and avoid sudden changes in temperature [60].
6.2. Longitudinal changes in lung function
A cross-sectional study suggested that restrictive abnormalities may increase with increasing
age in childhood [53]. A longitudinal study of children aged 5–18 years demonstrated at
baseline the children mainly had obstructive lung function abnormalities [61]. At follow up 4
years later, the number of children with obstructive or restrictive lung function abnormalities
had increased, but obstructive abnormalities were more common [61]. Retrospective analysis
of results from 413 SCD children aged between 8 and 18 years, however, demonstrated an
increased prevalence of restrictive abnormalities with increasing age [62]. In two cohorts of
SCD children, one of which was followed for 2 years and the other for 10 years, lung function
deteriorated in the SCD children compared to contemporaneously studied ethnic and age
matched controls. This was the first longitudinal study to include contemporaneously studied
ethnic and age-matched controls [39]. In the cohort followed for 10 years restrictive abnor-
malities became more common. The rate of deterioration in lung function was greater in the
younger children in whom ACS episodes were more common [39].
6.3. Aetiology of the lung function abnormalities
The obstructive lung function abnormalities seen in SCD children could be due to asthma. An
increased prevalence of asthma was reported in one study [15], but other studies have indicated
a similar incidence to that of non-SCD populations [63, 64]. Exhaled nitric oxide is elevated in
asthma due to the enhanced expression of inducible nitric oxide synthase inflamed airways.
Yet in prospective study of 50 SCD children and 50 controls the exhaled NO levels between
the two groups were similar and airway obstruction in the SCD children was not associated
with increased methacholine sensitivity or eosinophilic inflammation [55]. An alternative
explanation for the airway obstruction in SCD is the hyperdynamic pulmonary circulation due
to a raised cardiac output resulting from chronic anaemia [65]. Furthermore, in a study of 18
SCD children compared to 18 ethnic and age-matched controls, the SCD children had a
significantly higher respiratory system resistance, alveolar NO production and pulmonary
blood flow, but not airway NO flux. There was a significant correlation between alveolar NO
production and pulmonary blood flow, but not between airway NO flux and respiratory
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system resistance [66]. SCD patients have an increased pulmonary capillary blood volume
resulting from their chronic anaemia. In a study of 25 SCD children and 25 ethnic origin
matched controls, the SCD children had significantly both higher airway obstruction and
pulmonary capillary blood volume before and after bronchodilator. In the SCD children there
was a significant correlation between the pulmonary capillary blood volume and the increased
airways airway obstruction [67]. Furthermore, transfusion in SCD children has been shown to
acutely increase airway obstruction and this was significantly related to an increase in
pulmonary capillary blood volume [68]. Those results suggest that the airway obstruction seen
in SCD children, at least in some, relates to their increased pulmonary capillary blood flow
rather than bronchial hyper-reactivity. The clinical implication of those results is that SCD
children with airway obstruction may have only limited benefit from bronchodilators and this
should be formally tested (see below). Strategies to reduce anaemia and the increased pulmo-
nary capillary blood volume, such as hydroxyurea, may be beneficial in those who remain
symptomatic despite optimisation of bronchodilator therapy.
7. Recommendations regarding routine respiratory monitoring
The most rapid deterioration in lung function occurs in very young children [39], thus routine
respiratory monitoring should begin early, that is, as soon as the child can undertake the
measurements (usually from 4 years of age) on an annual basis. Such monitoring is to enable
early detection of a child whose respiratory function is deteriorating and needs escalation of
treatment. Equally paired lung function assessments can determine the efficacy of treatment
for an individual (see below). Young children, however, have limited ability to perform lung
function tests and detailed lung function testing is not available in all centres. As a conse-
quence, in those less than 5 years of age, impulse oscillometry is recommended as this does
not require volitional input by the child; in older children spirometry gives additional
information. Both techniques are applicable to developed or low resource settings (if in the
latter a hand-held spirometer is used). Assessment of lung volume is also additive in older
children as this will identify those starting to develop restrictive abnormalities, but the relevant
techniques are expensive, particularly plethysmography. Assessment of lung volume by
measurement of functional residual capacity by helium gas dilution is more generalisable in
developed settings. It is important that children with wheeze are not assumed to have asthma
as wheeze in SCD may have other causes. It is therefore important that they undergo assess-
ment for bronchial hyper-reactivity according to their lung function, those with airway
function less than 70% of predicted should receive a bronchodilator and those with better
airway function, better than 70% predicted, should receive either a cold air or exercise
challenge. A methacholine challenge should not be used as this can precipitate an ACS. To
ensure all children are appropriately diagnosed as having AHR undertaking both a cold air
and exercise challenge should be considered, as some children respond only to one type of
challenge and not the other [69]. Theoretically, any bronchial challenge could precipitate a crisis
although this has only been reported with a metacholine challenge. An alternative approach
in a child with recurrent wheeze, particularly if they have an atopic family history, is to give
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them a trial of inhaled steroids, but importantly assess whether there has been any positive
effect using respiratory diary cards and preferably lung function assessments. Clinical trials
are required to evaluate the effectiveness of therapy for asthma in patients with SCD and
coincident asthma and whether this influences their respiratory outcomes.
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